An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
T2 Biosystems to Host Investor Call on March 20, 2024 to Unveil its T2Lyme Launch Plans and Provide Additional Business Updates
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
T2 Biosystems, Inc. (TTOO) announced a conference call to discuss T2Lyme Panel launch plans and business updates. The call will be held on March 20, 2024, at 8:30 a.m. Eastern Time. Investors can access the webcast at www.t2biosystems.com.
Positive
None.
Negative
None.
LEXINGTON, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that Company management will host a conference call to discuss the T2Lyme Panel launch plans and provide additional business updates before market open on Wednesday, March 20, 2024 beginning at 8:30 a.m. Eastern Time.
Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.t2biosystems.com, on the Investors page in the Events & Presentations section. To listen to the conference call, please dial 1-888-506-0062 (U.S./Canada) or 1-973-528-0011 (International), passcode 688651, approximately ten to five minutes prior to the start time.
About T2 Biosystems T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, is dedicated to improving patient care and reducing the cost of care by helping clinicians effectively treat patients faster than ever before. T2 Biosystems’ products include the T2Dx® Instrument, the T2Bacteria® Panel, the T2Candida® Panel, the T2Resistance® Panel, and the T2Biothreat™ Panel, and are powered by the proprietary T2 Magnetic Resonance (T2MR®) technology. T2 Biosystems has an active pipeline of future products, including the U.S. T2Resistance Panel, the Candida auris test, and the T2Lyme™ Panel. For more information, please visit www.t2biosystems.com.
Investor Contact: Philip Trip Taylor, Gilmartin Group ir@T2Biosystems.com 415-937-5406
FAQ
When will T2 Biosystems host a conference call to discuss T2Lyme Panel launch plans?
T2 Biosystems will host a conference call on March 20, 2024, at 8:30 a.m. Eastern Time.
Where can investors access the webcast of the conference call?
Investors can access the webcast at www.t2biosystems.com on the Investors page in the Events & Presentations section.
What is the dial-in number for the conference call?
The dial-in number for the conference call is 1-888-506-0062 (U.S./Canada) or 1-973-528-0011 (International), passcode 688651.
t2 biosystems is developing innovative diagnostic products to improve patient health. with two fda-cleared products targeting sepsis – the cause of one out of two hospital deaths - and a range of additional products in development, t2 biosystems is an emerging leader in the field of in vitro diagnostics. our initial development efforts target sepsis, hemostasis, bacteria and lyme disease, which are areas of significant unmet medical need. the company is utilizing its proprietary t2 magnetic resonance platform, or t2mr®, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. at t2 biosystems, we know that our passion to advance the medical diagnostic landscape relies on our ability to attract and retain the very best people in the world – and to encourage them to flourish. we invite you to apply for one of our open positions at www